AML Clinical Trials in Tianjin, Tianjin Municipality
18 recruitingTianjin, Tianjin Municipality, China
Showing 1–18 of 18 trials
Recruiting
Phase 3
Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1
AMLRUNX1-RUNX1T1 Fusion Protein Expression
Institute of Hematology & Blood Diseases Hospital, China300 enrolled1 locationNCT06744504
Recruiting
Phase 1Phase 2
Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML
TreatmentAMLIDH1 Mutation
Institute of Hematology & Blood Diseases Hospital, China29 enrolled1 locationNCT06611839
Recruiting
Phase 1Phase 2
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Ovarian CarcinomaNSCLCSCLC+5 more
Jacobio Pharmaceuticals Co., Ltd.152 enrolled1 locationNCT04686682
Recruiting
Phase 1Phase 2
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07153068
Recruiting
Phase 2
Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML
AML (Acute Myeloid Leukemia)Allogeneic Hematopoietic Cell Transplantation (HCT)
Institute of Hematology & Blood Diseases Hospital, China134 enrolled5 locationsNCT07304232
Recruiting
Phase 1Phase 2
The Efficacy of Triple Regimen in Newly Diagnosed AML Patients With FLT3 Mutation
AMLFLT3 Gene Mutation
Institute of Hematology & Blood Diseases Hospital, China36 enrolled1 locationNCT06561880
Recruiting
Phase 1
A Study of BL-M11D1 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
Sichuan Baili Pharmaceutical Co., Ltd.130 enrolled8 locationsNCT05924750
Recruiting
Phase 1
uCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Acute Myeloid Leukemia (AML)T Lymphoblastic Leukemia/Lymphoma
Institute of Hematology & Blood Diseases Hospital, China12 enrolled1 locationNCT07109518
Recruiting
Not Applicable
MRD-positive AML Clinical Study
AML, Adult
Institute of Hematology & Blood Diseases Hospital, China120 enrolled1 locationNCT07131059
Recruiting
Not Applicable
Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
Acute Myeloid LeukemiaAML
Institute of Hematology & Blood Diseases Hospital, China184 enrolled1 locationNCT06386302
Recruiting
Phase 2
HAV Versus DAV/IAV Induction Regimen in Elderly Patients With AML
AML
Institute of Hematology & Blood Diseases Hospital, China60 enrolled1 locationNCT06744556
Recruiting
Phase 1Phase 2
The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors
AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710
Recruiting
Not Applicable
Intermediate-dose HAD Regimen for CEBPA Double-mutated AML
AML
Institute of Hematology & Blood Diseases Hospital, China148 enrolled1 locationNCT06529250
Recruiting
Phase 1
A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.
Acute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS)
Ascentage Pharma Group Inc.102 enrolled14 locationsNCT04275518
Recruiting
Phase 2
Efficacy of Venetoclax Combined with Intensive Chemotherapy in Different Subgroups of AML
AML (Acute Myelogenous Leukemia)
Institute of Hematology & Blood Diseases Hospital, China1,200 enrolled1 locationNCT06635681
Recruiting
Phase 1
A Clinical Trial of TQB3455 Tablets in Patients With Hematological Malignancies
Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.100 enrolled7 locationsNCT06550713
Recruiting
Phase 1
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
AML, Adult RecurrentNHL, Adult
Shengke Pharmaceuticals (Jiangsu) Limited, China60 enrolled2 locationsNCT05758610
Recruiting
Phase 1
A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Nanjing Chia-tai Tianqing Pharmaceutical72 enrolled1 locationNCT06049667